Pivotal KRYSTAL-12 confirmatory trial evaluating Krazati (adagrasib) meets primary endpoint of progression-free survival for patients with pretreated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer
Bristol Myers Squibb announced that the pivotal Phase III KRYSTAL-12 study, evaluating Krazati (adagrasib) as a monotherapy in patients with pretreated locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation, met the primary endpoint of progression-free survival (PFS) and the key secondary endpoint of overall response rate (ORR) as assessed by Blinded Independent Central Review (BICR) at final analysis for these endpoints.
The study remains ongoing to assess the additional key secondary endpoint of overall survival.
Results of the confirmatory trial showed that Krazati demonstrated a statistically significant and clinically meaningful benefit in PFS and ORR compared to standard-of-care chemotherapy as a second-line or later treatment for these patients. Krazati had no new safety signals and the safety data was consistent with the known safety profile.
“Today’s news is an important reinforcement of the power of a targeted therapy for patients with locally advanced or metastatic KRASG12C-mutated lung cancer. FDA approval of Krazati in the U.S. has allowed us to provide a new treatment option for these patients, and topline results of the KRYSTAL-12 confirmatory study will build greater trust in the medical and patient community,” said Abderrahim Oukessou, M.D., vice president, global program lead, Krazati, Bristol Myers Squibb. “
The company will complete a full evaluation of the available data and looks forward to sharing the results with the scientific community at an upcoming medical conference as well as discussing the results with health authorities.
The FDA granted accelerated approval for Krazati as a targeted treatment for patients with KRASG12C-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic therapy in December 2022. In 2023, Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization for Krazati as a targeted treatment option for adult patients with KRASG12C-mutated advanced NSCLC and disease progression after at least one prior systemic therapy followed by the European Commission (EC) in 2024.
In addition to KRASG12C-mutated NSCLC, Krazati and Krazati-based combinations have shown encouraging meaningful benefit in Phase II clinical trials across several tumors, including advanced colorectal cancer, pancreatic cancer and other solid tumors. In February, the FDA accepted for priority review the supplemental new drug application (sNDA) for Krazati in combination with cetuximab for the treatment of patients with previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC). The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins